Review articlePublished 2015
Aromatase Inhibitors and Osteoporosis - Risk, Prevention and Treatment Review
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Breast cancer is the most common cancer diagnosed and second leading cause of death among women in United States. Surgical resection with or without radiation remains the cornerstone of treatment for early stage breast cancer. Systemic adjuvant therapy with Tamoxifen or Aromatase Inhibitors (AIs) is indicated for Estrogen/Progesterone receptor (ER/PR) positive non metastatic breast cancer, depending upon their menopausal status. AIs are the drug of choice in postmenopausal women. They block or prevent estrogens from stimulating the growth of cancer by inhibiting aromatase from converting androgen into estrogen. According to an updated 2004 assessment from the American Society of Clinical Oncology, AIs are recommended to be used in adjuvant therapy initially or after Tamoxifen use for postmenopausal women with ER/PR positive breast cancer.
Subjects
OrthopaedicsAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalJournal of Osteoporosis and Physical Activity
- SubjectOrthopaedics
- BylineArticles whose byline prints “Wajeeha Razaq”
- BylineArticles whose byline prints “Takemi Tanaka”
- BylineArticles whose byline prints “Mohammad Abdu Razaq”
